Background: Although there is evidence about the beneficial effects of probiotics, their effects on aspirin-induced small bowel injuries have not been well examined. We evaluated the effects of the probiotic Lactobacillus gasseri OLL2716 (LG) on aspirin-induced small intestinal lesions, such as ulcers, erosions, reddened lesions, and bleeding. Summary: This study enrolled 64 patients who received aspirin for more than 1 month and provided written informed consent to be part of the study. The patients received 112 ml of yogurt containing LG or placebo twice daily for 6 weeks. Small bowel injuries were evaluated by capsule endoscopy before and after consuming the yogurt. The effect of LG on patient symptoms was also assessed using the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (FSSG) and Gastrointestinal Symptom Rating Scale (GSRS) questionnaires before and after 6 weeks of treatment. There was no significant difference in any baseline characteristics and the number of small bowel mucosal breaks between the 2 groups. In contrast with the placebo group, the LG group had significantly fewer small bowel mucosal breaks and reddened lesions after 6 weeks (p < 0.01). The FSSG and GSRS scores were also significantly improved in the LG group but not in the placebo group. Key Messages: This double-blind, placebo-controlled study found that LG may be useful in reducing aspirin-induced small bowel injuries and in mitigating gastrointestinal symptoms.

Journal Section:
Original Paper
Keywords:
Lactobacillus gasseri, Small bowel injuries, Low-dose aspirin
1.
Awtry EH, Loscalzo J: Aspirin. Circulation 2000;101:1206-1218.
[PubMed]
https://doi.org/10.1161/01.CIR.101.10.1206
2.
Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-830.
[PubMed]
https://doi.org/10.1136/bmj.310.6983.827
3.
Satoh K, Yoshino J, Akamatsu T, Itoh T, Kato M, Kamada T, et al: Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol 2016;51:177-194.
[PubMed]
https://doi.org/10.1007/s00535-016-1166-4
4.
Targownik LE, Metge CJ, Leung S, Chateau DG: The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008;134:937-944.
[PubMed]
https://doi.org/10.1053/j.gastro.2008.01.010
5.
Takeuchi K, Satoh H: NSAID-induced small intestinal damage - roles of various pathogenic factors. Digestion 2015;91:218-232.
[PubMed]
https://doi.org/10.1159/000374106
6.
Endo H, Sakai E, Kato T, Umezawa S, Higurashi T, Ohkubo H, et al: Small bowel injury in low-dose aspirin users. J Gastroenterol 2015;50:378-386.
[PubMed]
https://doi.org/10.1007/s00535-014-1028-x
7.
Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al: Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19:576-585.
[PubMed]
https://doi.org/10.1038/nm.3145
8.
Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, et al: Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol 2015;67:128-139.
[PubMed]
https://doi.org/10.1002/art.38892
9.
Sun J, Furio L, Mecheri R, van der Does AM, Lundeberg E, Saveanu L, et al: Pancreatic β-cells limit autoimmune diabetes via an immunoregulatory antimicrobial peptide expressed under the influence of the gut microbiota. Immunity 2015;43:304-317.
[PubMed]
https://doi.org/10.1016/j.immuni.2015.07.013
10.
Cox A, West NP, Cripps AW: Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol 2015;3:207-215.
[PubMed]
https://doi.org/10.1016/S2213-8587(14)70134-2
11.
Szajewska H, Shorka A, Ruszcznski M, Gieruszczak-Bialek D: Meta-analysis: lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007;25:871-881.
[PubMed]
https://doi.org/10.1111/j.1365-2036.2007.03282.x
12.
Ooi LG, Liong MT: Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci 2010;11:2499-2522.
[PubMed]
https://doi.org/10.3390/ijms11062499
13.
Guo Z, Liu XM, Zhang QX, Shen Z, Tian FW, Zhang H, et al: Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis 2011;21:844-850.
[PubMed]
https://doi.org/10.1016/j.numecd.2011.04.008
14.
Endo H, Higurashi T, Hosono K, Sakai E, Sekino Y, Iida H, et al: Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol 2011;46:894-905.
[PubMed]
https://doi.org/10.1007/s00535-011-0410-1
15.
Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, et al: Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol 2004;39:888-891.
[PubMed]
https://doi.org/10.1007/s00535-004-1417-7
16.
Svedlund J, Sjodin I, Dotevall G: GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33:129-134.
[PubMed]
https://doi.org/10.1007/BF01535722
17.
Watanabe T, Takeuchi T, Handa O, Sakata Y, Tanigawa T, Shiba M, et al: A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage. PLoS One 2015;10:e0122330.
[PubMed]
https://doi.org/10.1371/journal.pone.0122330
18.
Endo H, Hosano K, Inamori M, Nozaki Y, Yoneda K, Fujita K, et al: Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol 2009;44:544-549.
[PubMed]
https://doi.org/10.1097/MPG.0000000000001325
19.
Watanabe T, Sugimori S, Kameda N, Machida H, Okazaki H, Tanigawa T, et al: Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008;6:1279-1282.
[PubMed]
https://doi.org/10.1016/j.cgh.2008.06.021
20.
Mizukami K, Murakami K, Abe T, Inoue K, Uchida M, Okimoto T, et al: Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol 2011;46:5117-5122.
[PubMed]
https://doi.org/10.3748/wjg.v17.i46.5117
21.
Fujimori S, Takahashi Y, Gudis K, Seo T, Ehara A, Kobayashi T, et al: Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol 2011;46:57-64.
[PubMed]
https://doi.org/10.1007/s00535-010-0332-3
22.
Kurokawa S, Katsuki S, Fujita T, Saitoh Y, Ohta H, Nishikawa K, et al: A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol 2014;49:239-244.
[PubMed]
https://doi.org/10.1007/s00535-013-0805-2
23.
Lai Y, Zhong W, Yu T, Xia ZS, Li JY, Ouyang H, et al: Rebamipide promotes the regeneration of aspirin-induced small-intestine mucosal injury through accumulation of β-Catenin. PLoS One 2015;10:e0132031.
[PubMed]
https://doi.org/10.1371/journal.pone.0132031
24.
Watari I, Oka S, Tanaka S, Aoyama T, Imagawa H, Shishido T, et al: Effectiveness of Polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterol 2013;13:108.
[PubMed]
https://doi.org/10.1186/1471-230X-13-108
25.
Kawano M, Miyoshi M, Ogawa A, Sakai F, Kadooka Y: Lactobacillus gasseri SBT2055 inhibits adipose tissue inflammation and intestinal permeability in mice fed a high-fat diet. J Nutr Sci 2016;5:e23.
[PubMed]
https://doi.org/10.1017/jns.2016.12
26.
Emara MH, Mohamed SY , Abdel-Aziz HR: Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. Therap Adv Gastroenterol 2014;7:4-13.
[PubMed]
https://doi.org/10.1177/1756283X13503514
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.